Stopped: For strategic reasons
The purpose of this study is to investigate the safety of multiple oral doses of Lu AG06474, how well the doses are tolerated, and what the body does to the drug after administering it to healthy young participants. This study also aims to compare how the body absorbs and uses Lu AG06474 when it is given in capsule form versus when it is given as an oral solution.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Parts A and B: Number of Participants with Treatment Emergent Adverse Events (AEs)
Timeframe: Up to Day 10
Part A: Electrocardiogram (ECG) Parameter (delta QTcF) on Day 5
Timeframe: Day 5
Part A: AUC0-Ï„: Area Under the Lu AG06474 Plasma Concentration Curve During Dosing Interval
Timeframe: Predose to Day 7
Parts A and B: Cmax: Maximum Observed Plasma Concentration of Lu AG06474
Timeframe: Predose to Day 6
Parts A and B: Tmax: Nominal Time Corresponding to the Occurrence of Cmax
Timeframe: Predose to Day 6
Parts A and B: t½: Apparent Elimination Half-life of Lu AG06474
Timeframe: Predose to Day 6
Part B: AUC0-infinity: Area Under the Lu AG06474 Plasma Concentration Curve From Zero to Infinity
Timeframe: Predose to Day 6
Part A: Accumulation Index
Timeframe: Predose to Day 7
Part B: Frel: Relative Bioavailability
Timeframe: Predose to Day 6